SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Principal Financial Group issued $400 million in senior notes due 2037 pursuant to a definitive indenture agreement, representing a material debt financing transaction that affects the company's capital structure and leverage.
View raw filing on EDGAR →The disclosure announces a quarterly cash dividend of $0.525 per share declared by the Board of Directors. While dividend declarations are routine corporate actions, this is material to investors as it affects shareholder returns and signals the company's capital allocation and financial health. However, it does not fit neatly into the more specific event categories (not an earnings release, executive change, M&A, impairment, or other defined event types), warranting classification as other_material.
View raw filing on EDGAR →Oncolytics disclosed initial preclinical data for pelareorep in combination with RAS inhibitor modalities and announced plans for additional studies. For a biotech company, preclinical data announcements and new study plans represent material developments in the clinical pipeline that would affect investor assessment of the company's prospects, though the disclosure does not fit the more specific event categories (not an earnings release, executive change, M&A, impairment, or litigation).
View raw filing on EDGAR →NJNG submitted a base rate case filing with the New Jersey Board of Public Utilities on June 1, 2026, along with related filings for BGSS, CIP, and Energy Efficiency programs. While this is a regulatory filing that could materially affect future utility rates and revenues, it does not fit neatly into the standard 8-K taxonomy (not M&A, not an executive change, not a restatement, etc.). This is disclosed under Item 7.01 (Regulation FD Disclosure) as an investor-relevant regulatory event that warrants classification as other_material.
View raw filing on EDGAR →The Amended and Restated Certificate of Incorporation and Bylaws were adopted following the business combination closing, materially modifying shareholder rights through elimination of redemption rights, authorization of new share capital structure, classified board provisions, exclusive forum selection, and transfer restrictions on founder/employee shares.
View raw filing on EDGAR →IN8bio terminated its Controlled Equity Offering Sales Agreement with Cantor Fitzgerald, which had been a material financing mechanism established in November 2022, eliminating the Company's ability to raise capital through that at-the-market offering program.
View raw filing on EDGAR →The Company disclosed an investor presentation describing its business and "Path Forward Plan update" via Regulation FD. While the disclosure itself is routine (Item 7.01 furnishing), the substantive content—a strategic plan update—could be material to investors assessing the Company's direction and operational strategy. However, without access to the actual presentation content, the materiality and specific event type cannot be definitively determined; this is classified as other_material pending review of Exhibit 99.1.
View raw filing on EDGAR →The company implemented a 1-for-11 reverse stock split and reduced authorized shares from 500 million to 100 million, both approved by stockholders and effectuated via Certificate of Amendment filed May 29, 2026, materially altering the capital structure and per-share metrics.
View raw filing on EDGAR →The company disclosed a material modification to the rights of security holders, with details incorporated by reference from Item 5.03 (Amendments to Articles of Incorporation or Bylaws); the specific nature of the modification cannot be determined without access to the referenced Item 5.03 content.
View raw filing on EDGAR →The company announced updated clinical trial data for drug candidates EIK1001 and EIK1003 presented at ASCO 2026, which is material to investor assessment of the company's pipeline progress and regulatory prospects.
View raw filing on EDGAR →HCI Group entered into comprehensive reinsurance agreements for its four insurance subsidiaries covering June 1, 2026 through May 31, 2027, with total net consolidated reinsurance premiums of approximately $381.2 million to third parties. While this is a material definitive agreement (Item 1.01) involving significant financial commitments and risk transfer arrangements across three reinsurance towers, it does not fit cleanly into the ma_activity category, which typically covers acquisitions, dispositions, mergers, or changes of control. This is a routine but material operational reinsurance placement that would affect investor assessment of the company's catastrophe risk mitigation strategy and financial obligations.
View raw filing on EDGAR →Jade Biosciences disclosed interim Phase 1 trial results for JADE101, a novel monoclonal antibody candidate for IgAN treatment, showing favorable safety, potent IgA reductions (approximately 70% at the 700 mg dose), and a differentiated pharmacokinetic profile. The results were presented via conference call and webcast and represent a material clinical development milestone affecting investor assessment of the company's pipeline progress and product viability.
View raw filing on EDGAR →Teleflex announced a $500 million private offering of Senior Notes due 2032 to refinance its 4.625% Senior Notes due 2027, materially affecting the company's capital structure and debt maturity profile.
View raw filing on EDGAR →Strategy Inc disclosed multiple material operational updates including ATM program activity generating $128.3M in net proceeds, bitcoin sales of $2.5M, dividend declarations across five preferred stock series, and maintenance of an $900M USD Reserve. These disclosures collectively constitute material information about the registrant's financing, asset management, and shareholder distributions.
View raw filing on EDGAR →Welltower announced an increase in its quarterly common stock dividend from an implied prior level to $0.85 per share, effective Q2 2026. While dividend announcements are material to investors and affect total shareholder return expectations, this disclosure does not fit cleanly into the standard taxonomy categories (earnings_release, exec_compensation, etc.). The announcement is a capital allocation decision rather than a financial result, executive action, or compensation arrangement, making "other_material" the most appropriate classification.
View raw filing on EDGAR →Manhattan Associates announced a 6% global headcount reduction with estimated cash charges of $7–9 million in Q2 2026 for severance and termination benefits, representing a material restructuring event affecting the company's cost structure and near-term financial results.
View raw filing on EDGAR →Fulcrum announced discontinuation of its pociredir program for sickle cell disease and initiation of a comprehensive strategic review. While this represents a material operational change affecting the company's pipeline and strategic direction, it does not fit neatly into more specific categories (not a restatement, impairment charge, going-concern disclosure, or M&A activity per se). The strategic review language suggests potential future M&A or restructuring, but the disclosed event itself is the program discontinuation and review initiation.
View raw filing on EDGAR →IDEAYA disclosed complete Phase 2/3 trial data for darovasertib combination in metastatic uveal melanoma, meeting the primary endpoint with statistically significant PFS improvement (6.9 vs 3.1 months, p<0.0001) and favorable secondary endpoints, representing a significant clinical milestone supporting anticipated NDA filing.
View raw filing on EDGAR →Avis Budget issued $300 million in 8.000% Senior Notes due 2031 on May 29, 2026, intending to use proceeds to redeem a portion of its 5.750% Senior Notes due 2027. While this is a material debt issuance and refinancing activity affecting the company's capital structure and financial obligations, it does not fit cleanly into the more specific event categories (ma_activity applies to acquisitions/dispositions, not debt issuances; covenant_breach requires a violation). The disclosure is material to investors as it affects leverage, interest expense, and debt maturity profile, but the primary action is a routine debt offering and refinancing rather than a discrete material event like M&A, impairment, or covenant breach.
View raw filing on EDGAR →Callaway Golf announced full repayment of its Term Loan B, a material debt reduction event that improves the company's financial position and reduces leverage. While this is positive news rather than a distress signal, the complete repayment of a term loan facility is material to investors assessing the registrant's capital structure and financial health. This does not fit neatly into the more specific event categories (not a restatement, covenant breach, going concern, or impairment), making "other_material" the most appropriate classification.
View raw filing on EDGAR →LSB Industries disclosed an acceleration of a previously announced turnaround at its Pryor, Oklahoma facility from July 2026 to immediate commencement on May 28, 2026. While the company states the change in timing should not affect expected duration or cost estimates, the acceleration of a major capital project affecting production capacity and customer commitments is material to investors assessing operational risk and near-term financial performance. This does not fit neatly into the more specific event categories (not M&A, impairment, covenant breach, or litigation), making "other_material" the appropriate classification.
View raw filing on EDGAR →In connection with the spin-off completion, the registrant amended and restated its certificate of incorporation and bylaws, effected a stock split increasing authorized shares, and changed its name from Enviri II Corporation to Enviri Corporation, materially restructuring the post-spin entity's capital stock and governance structure.
View raw filing on EDGAR →OceanFirst created a new class of preferred stock designated as NVCE Stock via Certificate of Designations filed with Delaware, establishing specific rights, preferences, and conversion terms tied to the Warburg Pincus investment and merger consummation.
View raw filing on EDGAR →The Board has initiated a "comprehensive review of strategic alternatives aimed at maximizing shareholder value," which signals potential M&A activity, restructuring, or other transformative corporate actions. While the disclosure does not confirm a specific transaction, the announcement of a formal strategic review is material to investors as it indicates the company is actively considering significant changes to its business structure or ownership. This does not fit neatly into the M&A taxonomy (which typically requires entry into, completion, or termination of a transaction) but is clearly material and warrants classification as other_material pending further developments.
View raw filing on EDGAR →The filing discloses a 1-for-15 reverse stock split effective June 2, 2026, which materially affects the capital structure and share count (from ~16.267 million to ~1.084 million shares outstanding). While reverse splits are sometimes routine capital management actions, this event is material to investors as it affects share price, voting power, and equity award calculations. The disclosure does not fit the more specific event categories (not an earnings release, executive change, M&A, impairment, or delisting notice), making "other_material" the most appropriate classification.
View raw filing on EDGAR →The disclosure announces the commencement of separate trading of Class A ordinary shares and Warrants previously bundled in Units, effective June 4, 2026. While this is a routine post-IPO structural event for special purpose acquisition companies (SPACs), it materially affects how investors can trade the underlying securities and represents a significant change in the capital structure's tradability. This does not fit neatly into the more specific event categories (not an earnings release, executive change, M&A activity, or financial restatement), making "other_material" the appropriate classification.
View raw filing on EDGAR →Oruka entered into a First Amendment to its IL-23 License Agreement with Paragon Therapeutics on May 29, 2026, expanding the Field to include inflammatory bowel disease—a significant therapeutic expansion for the Company's lead candidate ORKA-001. While this is a material licensing amendment affecting the Company's development rights and commercial scope, it does not fit cleanly into the more specific event categories (not an M&A transaction, not a covenant breach, not a restatement or going-concern issue). The expansion of therapeutic indications and the conditional restrictions on dosing timelines represent a material modification to the Company's intellectual property and development strategy.
View raw filing on EDGAR →The filing discloses presentation of clinical data at the American Society of Clinical Oncology Annual Meeting via press release (Item 8.01). For a clinical-stage oncology company, clinical data presentations at major medical conferences are typically material to investors assessing pipeline progress and competitive positioning, though the 8-K itself provides minimal detail. Without access to the actual press release content, the materiality and specific event classification cannot be definitively determined, warranting the broader "other_material" classification.
View raw filing on EDGAR →The disclosure announces presentation of clinical data at the American Society of Clinical Oncology Annual Meeting by the company's wholly-owned subsidiary Citius Oncology. While clinical data presentations can be material to investors evaluating pipeline progress and competitive positioning, the filing does not specify the nature, significance, or outcomes of the data presented. Without details on efficacy, safety, or regulatory implications, this is best classified as other_material rather than a more specific event type.
View raw filing on EDGAR →The Company disclosed a $2,000 deposit to extend its business combination deadline from June 2, 2026 to July 2, 2026. This is a material event for a SPAC (special purpose acquisition company) as it signals the Company is actively managing its timeline to complete an initial business combination and avoid liquidation. While not fitting neatly into the standard taxonomy categories, the extension of a critical deadline is material to investors assessing the Company's ability to execute its stated purpose.
View raw filing on EDGAR →BlockchAIn Digital Infrastructure entered into a 15-year Electric Service Agreement with a utility provider on May 27, 2026, securing up to 65,000 kilovolt-amperes of power for its flagship CLT01 data center campus with a minimum monthly demand charge of $400,000. This long-term operational contract is material to the company's data center infrastructure business and investor assessment of growth capacity and operational sustainability.
View raw filing on EDGAR →Barings BDC entered into a new Credit Support Agreement on May 29, 2026, replacing a prior agreement and providing approximately $11 million in credit support for two legacy portfolio companies. The prior agreement was terminated with a cash settlement of $67,027,611 from the Adviser to the Company, representing a material restructuring of credit support arrangements with explicit downside protection on unrealized investments and fee waivers by the Adviser.
View raw filing on EDGAR →The Company's Board approved an amendment to expand its common stock repurchase program by an additional $5 million, effective June 1, 2026. While share repurchases can signal management confidence and affect capital allocation, this disclosure does not fit neatly into the more specific event categories (it is not an earnings release, executive change, M&A activity, or other defined material event). The materiality stems from the capital commitment and potential impact on shareholder value and earnings per share, warranting classification as other_material.
View raw filing on EDGAR →Dropbox announced authorization of a $900 million share repurchase program on June 1, 2026, representing a material capital allocation decision.
View raw filing on EDGAR →Sensata announced early tender results for debt tender offers and increased the total cash consideration from $350 million to $400 million across three series of senior notes. While this is a material capital structure event affecting debt obligations, it does not fit cleanly into the more specific categories (ma_activity applies to acquisitions/dispositions, not debt repurchases; covenant_breach requires a default trigger). The increase in tender offer size and announcement of results constitute material disclosure to investors regarding the company's debt management strategy.
View raw filing on EDGAR →The board determined on May 8, 2026 that the Company cannot complete an initial business combination and will liquidate and dissolve, ceasing operations and redeeming public shares from the trust account. While this is a terminal event for the SPAC, it does not fit the specific "bankruptcy_filing" category (no formal bankruptcy petition) but represents a material liquidation that fundamentally affects shareholder rights and value.
View raw filing on EDGAR →The Company's board determined on May 8, 2026 that it would not complete an initial business combination and would begin liquidating and dissolving. While this is a terminal event for the SPAC, it does not fit the "bankruptcy_filing" category (no formal bankruptcy petition) nor "going_concern" (which typically addresses doubt about continuation, not a deliberate liquidation decision). The disclosure is material as it fundamentally affects shareholder rights and value, warranting classification as "other_material."
View raw filing on EDGAR →The filing discloses the Company's quarterly determination of net asset value (NAV) and NAV per Class A unit as of March 31, 2026, including a detailed breakdown of assets ($755.6M), liabilities ($302.5M), resulting NAV of $453.2M, and NAV per unit of $116.25. While NAV disclosures are routine for real estate investment entities, this quarterly valuation is material to investors in assessing the underlying value of their units. However, this does not fit cleanly into the standard 8-K event taxonomy (not earnings, M&A, impairment, litigation, etc.), making "other_material" the most appropriate classification.
View raw filing on EDGAR →Elite Pharmaceuticals disclosed filing an Abbreviated New Drug Application (ANDA) with the FDA for a generic anticoagulant product via Item 7.01 Regulation FD Disclosure. While this is a significant regulatory milestone for a pharmaceutical company that could materially affect future revenue and competitive position, it does not fit neatly into the more specific event categories (not an earnings release, M&A activity, impairment, or executive change). The ANDA filing represents material business development activity that would affect a reasonable investor's assessment of the company's pipeline and prospects.
View raw filing on EDGAR →Verano announced a 1-for-5 reverse stock split effective June 11, 2026, reducing outstanding shares from 364.4 million to 72.9 million and authorized shares from 5 billion to 1 billion. While reverse splits are material corporate actions affecting share structure and investor holdings, they do not fit neatly into the specific event categories (not M&A, not a restatement, not an impairment, not a delisting risk per se). This is a significant capital structure modification that would affect a reasonable investor's assessment of the company, warranting classification as a material event outside the more specific taxonomy.
View raw filing on EDGAR →The filing discloses a material strategic transformation involving a company name change (Sharps Technology to SkyAI), ticker symbol changes (STSS to SKYA, STSSW to SKYAW), and a fundamental pivot from legacy operations to an AI-driven financial platform focused on emerging markets. While Item 5.03 typically covers changes in bylaws or articles of incorporation, the substantive disclosure centers on a strategic business transformation with significant operational, geographic, and technological repositioning. This does not fit neatly into the more specific event categories (not an M&A transaction, not an earnings release, not an executive change) but clearly would materially affect a reasonable investor's assessment of the company's direction and risk profile.
View raw filing on EDGAR →The filing discloses the launch of "Vertical Edge," a new edge data center platform representing the completion of a three-platform business model integrating owned data center infrastructure with existing GPU provisioning and financing operations. While this is a significant strategic business development, it does not fit neatly into standard 8-K event categories (not M&A, not an earnings release, not an executive change, impairment, or other defined event type). The announcement of a major new business platform and strategic pivot would be material to investors assessing the company's business model and growth strategy.
View raw filing on EDGAR →Soulpower Acquisition Corporation issued an unsecured promissory note (B Note) for up to $2.5 million to Soulpower Management LLC on May 29, 2026. The note is forgiven upon consummation of the initial business combination but becomes due upon liquidation or default. While this creates a direct financial obligation under Item 2.03, it does not fit cleanly into the standard taxonomy categories—it is neither a covenant breach (no violation disclosed), nor a dilutive issuance (debt, not equity), nor a typical M&A activity. The material nature stems from the $2.5 million obligation and its connection to the sponsor's financing of the SPAC's operations.
View raw filing on EDGAR →MicroVision announced plans to seek shareholder approval for an amendment to its certificate of incorporation to authorize a reverse stock split at a ratio between 1-for-5 and 1-for-15, with the exact ratio to be determined by the Board. While reverse stock splits are sometimes routine, this disclosure involves a material corporate action requiring shareholder approval and would affect the total mix of information available to investors regarding capital structure and potential dilution implications. The filing is solicitation material for the 2026 Annual Meeting of Shareholders, but does not fit neatly into the more specific event categories (it is not an earnings release, executive change, M&A activity, restatement, auditor change, going concern, impairment, shareholder vote results, delisting risk, bankruptcy, covenant breach, cybersecurity incident, dilutive issuance, or material litigation).
View raw filing on EDGAR →The filing discloses a 1-for-10 reverse stock split effective June 2, 2026, approved by the Board and shareholders (85.4% consent), along with amendments to the Articles of Incorporation reducing authorized shares from 1 billion to 100 million and increasing par value from $0.0001 to $0.001. While reverse splits are routine capital structure events, this disclosure does not fit cleanly into the standard taxonomy categories (not an earnings release, executive change, M&A, impairment, or delisting notice). The event is material to investors as it affects share count, trading symbol temporarily, and capital structure, warranting disclosure under Item 8.01 (Other Events).
View raw filing on EDGAR →Summit Therapeutics disclosed results from two clinical trials (AK112-206 Phase II and HARMONi-6 Phase III) for ivonescimab in colorectal cancer via press releases and a scheduled investor conference call. While this represents material clinical trial data that would affect investor assessment of the company's pipeline, it does not fit the specific "earnings_release" category (which typically refers to financial results) nor any other more specific event type. This is a material clinical development disclosure appropriately classified as other_material.
View raw filing on EDGAR →Via Renewables announced the redemption of 1,884,935 shares of Series A Preferred Stock at $25.00 per share (approximately $47.1 million in principal), representing a material capital transaction. While redemptions of preferred stock are routine corporate actions, the magnitude and the fact that it is disclosed in an 8-K Item 8.01 indicates the company views it as material to investors. This does not fit neatly into the more specific event categories (not M&A, not an impairment, not a covenant breach), making "other_material" the most appropriate classification.
View raw filing on EDGAR →Public Storage disclosed an operating update for same-store facilities covering April 1 through May 28, 2026 and 2025, including key metrics such as average annual contract rent per square foot, churn rates, and occupancy levels, constituting a material event affecting investor assessment of the company's business performance and trends.
View raw filing on EDGAR →Samsara Inc. completed a reincorporation from Delaware to Nevada effective June 1, 2026, materially modifying shareholder rights by changing the governing law and corporate governance documents. The reincorporation fundamentally altered the legal framework governing the company and its shareholders, as detailed in an Information Statement filed May 11, 2026.
View raw filing on EDGAR →The Amendment expands the Field of the SPY003 License Agreement from inflammatory bowel disease to all therapeutic uses, subject to time-based dosing restrictions. This materially broadens the Company's development rights and commercial potential for SPY003, affecting the scope of its pipeline and strategic optionality. While not a traditional M&A, restatement, or executive event, the expansion of licensed rights and removal of field restrictions is material to investors assessing the registrant's asset base and development strategy.
View raw filing on EDGAR →